Recursion Pharmaceuticals (NASDAQ:RXRX) Posts Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) released its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the business posted ($0.42) earnings per share. Recursion Pharmaceuticals’s quarterly revenue was down 57.8% compared to the same quarter last year.

Recursion Pharmaceuticals Stock Down 2.1 %

Shares of NASDAQ RXRX opened at $7.51 on Friday. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -4.91 and a beta of 0.86. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average price of $7.72 and a two-hundred day moving average price of $7.08. Recursion Pharmaceuticals has a 12 month low of $5.60 and a 12 month high of $14.12.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Finally, Leerink Partners lowered their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.